Should the usual threshold for prostate biopsy be lowered from 4.0 to 2.5 ng/mL for healthy men with a life expectancy of well over 10 years?

The National Cancer Institute estimated that 240,890 men would be diagnosed with prostate cancer in the United States in 2011. Many clinicians believe the disease is being overdiagnosed and overtreated, yet some researchers have advocated decreasing the PSA threshold for prostate biopsy from the conventional 4.0 ng/mL to 2.5 ng/mL in an attempt to pick up prostate cancers that are now being missed. Critics say this could exacerbate the problem of overdiagnosis and lead to even more men being treated unnecessarily.

Renal & Urology News would like to know what you think, so please answer the following poll question.

Leave a comment below on why you chose your answer. If your answer doesn't match one of our choices, please let us know why.

More in Polls & Surveys

Does concern about regulatory sanctions affect your prescribing of opiates?

Some pain specialists say physicians have been scaling back their prescribing of opiates or not prescribing them at all.

Are non-economic damage caps in malpractice cases fair to plaintiffs?

States have launched or are considering a number of initiatives aimed at reining in medical malpractice litigation and costs.

Should active surveillance for PCa be used more cautiously for black men?

A study found that black men on active surveillance are more likely to experience disease progression and to abandon AS.